Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director
HaemaLogiX Ltd, a clinical stage Australian biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, has appointed Dr Chris Baldwin as Chief Executive Officer and Managing Director, having commenced 5 January 2026.
Holding a PhD in Chemical Engineering from the University of Cambridge, for which he was selected as British Marshall Scholar, Baldwin brings more than two decades of experience spanning scientific research, operational leadership, capital markets and commercial strategy across Australia, Asia–Pacific, Europe and the United States.
Having begun his career in academia as an Associate Professor of Chemical Engineering at Iowa State University, Baldwin then transitioned into industry, joining McKinsey & Company in New York. Subsequent roles have spanned C-suite and founder positions across ASX-listed and international biotechnology and precision therapeutics companies.
“HaemaLogiX has built a compelling immunotherapy platform with the potential to address significant unmet needs for patients with blood cancers,” Baldwin said. “I am excited to join the Company at this important stage of growth and to work with the Board and team to advance our clinical programs, build strategic partnerships and create long-term value for patients and investors.”
Illumina appoints Susan Martin as General Manager, ANZ
Most recently, Martin served as Managing Director, Australia and New Zealand at Johnson &...
Monash University signs MOU with TGA Academic Outreach Program
The program fosters collaboration across research, knowledge exchange and education to support...
Report: Economic value of NATA accreditation estimated at $488–712m annually
A UTS report has explored the economic and social value of National Association of Testing...
